Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Cyrille Hulin et al.|Nature Medicine|2024Cited by 109
Response to pneumococcal vaccination in multiple myelomaLoïc Renaud, Xavier Leleu, Susanna Schraen et al.|Cancer Medicine|2019Cited by 24
Carfilzomib weekly 20/56 mg/m<sup>2</sup>, lenalidomide and dexamethasone for early relapsed refractory multiple myelomaValentine Richez, Xavier Leleu, Arthur Bobin et al.|American Journal of Hematology|2018Cited by 7
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experiencePhilippe Moreau, Aurore Perrot, Cyrille Hulin et al.|Blood Cancer Journal|2025Cited by 2
Carfilzomib weekly 20/56mg/m², lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.Valentine Richez, Xavier Leleu, Stéphanie Guidez et al.|Journal of Clinical Oncology|2018Cited by 2